NASDAQ:NBP Novabridge Biosciences Q2 2026 Earnings Results & Report $0.82 +0.03 (+3.89%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.67%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Novabridge Biosciences reported Q2 2026 earnings on August 20, 2026. The company reported EPS of -$0.1610. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 20, 2026TimeBefore Market Opens Novabridge Biosciences EPS ResultsActual EPS-$0.1610Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANovabridge Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Novabridge Biosciences Q2 2026 Earnings FAQ Did Novabridge Biosciences beat earnings estimates for Q2 2026? Novabridge Biosciences (NASDAQ:NBP) reported earnings of -$0.1610 per share for Q2 2026. The report was announced on Thursday, August 20, 2026. Novabridge Biosciences Earnings HeadlinesVisara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD1 hour ago | globenewswire.comNovaBridge Biosciences to Participate in Upcoming Investor ConferencesNovember 9, 2026 | finance.yahoo.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 18 at 1:00 AM | Profits Run (Ad)Financial Review: Xenon Pharmaceuticals (NASDAQ:XENE) vs. Novabridge Biosciences (NASDAQ:NBP)November 7, 2026 | americanbankingnews.comBrokers Offer Predictions for NBP FY2026 EarningsNovember 7, 2026 | americanbankingnews.comNovaBridge Biosciences (NBP) Stock Forecast & Price TargetNovember 4, 2026 | tipranks.comSee More Novabridge Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novabridge Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novabridge Biosciences and other key companies, straight to your email. Email Address About Novabridge BiosciencesNovabridge Biosciences (NASDAQ:NBP) (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use. Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles. View Novabridge Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.